CEO David Lukes highlighted that 2025 marked the company's first year as a public entity, stating "The fourth quarter capped an incredible first year as a public company for Curbline, and I couldn't ...
Silexion Therapeutics announces an expanded development plan for SIL204, targeting KRAS-driven cancers, to be presented at the NeauxCancer 2025 Conference. Silexion Therapeutics Corp., a biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results